Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1738008

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gene Therapies
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of (1) the progress in using, and (2) the suitability of, the Innovative Medicines Fund in providing NHS access to gene therapies in England.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2124
answer	answer is ministerial correction date of answer 07/11/2024 answer text <p>The Innovative Medicines Fund (IMF) was launched in June 2022 and builds on the successful Cancer Drugs Fund to support patient access to the most promising new medicines, while further evidence is collected on their use to address clinical uncertainty. £340 million is available through the fund this financial year for the National Health Service to fund early access to the most promising treatments, including gene therapies, while additional data is collected that will inform a future National Institute for Health and Care Excellence (NICE) evaluation to decide whether the medicine should be routinely funded. The NICE has recommended two treatments for use through the IMF, both of which are gene therapies, which are:</p><ul><li>etranacogene dezaparvovec, for treating moderately severe or severe haemophilia B; and</li><li>exagamglogene autotemcel, for treating transfusion-dependent beta-thalassaemia in people aged 12 years old and over.</li></ul> answering member printed Baroness Merron question first answered 07/11/2024 16:10:23 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1738009

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with NHS England and the National Institute for Health and Care Excellence about access to innovative treatments for sickle cell disease.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2125
answer	answer is ministerial correction date of answer 04/11/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), including access to new and innovative treatments for a range of diseases and conditions.</p><p>The NICE makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating exagamglogene autotemcel within its licensed indication for treating sickle cell, and has not yet published final guidance.</p><p>The NICE will aim to publish guidance on any new, licensed treatment for sickle cell disease as soon as possible after licensing.</p> answering member printed Baroness Merron question first answered 04/11/2024 14:31:57 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1738010

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that new dementia treatments can be deemed cost-effective by the National Institute for Health and Care Excellence, in the light of the investment required to scale up diagnostics.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2126
answer	answer is ministerial correction date of answer 08/11/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance. The NICE only recommends medicines that offer additional health benefits to patients and their carers, and demonstrate value for money for the taxpayer.</p><p>The NICE is currently evaluating two new licensed disease-modifying treatments for Alzheimer’s disease and has been unable to recommend them in its draft guidance. The NICE concluded that the relatively small benefits they provide balanced against the overall cost of providing the treatments, including intensive monitoring for serious side effects, means that they cannot currently be considered good value for the taxpayer. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.</p><p>A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure that diagnostic and treatment capacity, and clinical pathway redesign and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.</p><p>The Government will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will also put Britain at the forefront of transforming treatment for dementia by backing more research into the disease. Part of this will be ensuring that we support manufacturers to develop products that are potentially cost effective to implement, and that new treatments assessed as clinically and cost effective are rolled out in a safe and timely way.</p><p>The Department funds dementia research via the National Institute for Health and Care Research (NIHR). Alongside Alzheimer’s Research UK, Alzheimer’s Society, and the People’s Postcode Lottery, the NIHR is funding the Blood Biomarker Challenge which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support diagnosis of dementia.</p> answering member printed Baroness Merron grouped question UIN HL2127 question first answered 08/11/2024 13:11:38 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1738011

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that disease-modifying dementia treatments are available through the NHS.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2127
answer	answer is ministerial correction date of answer 08/11/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance. The NICE only recommends medicines that offer additional health benefits to patients and their carers, and demonstrate value for money for the taxpayer.</p><p>The NICE is currently evaluating two new licensed disease-modifying treatments for Alzheimer’s disease and has been unable to recommend them in its draft guidance. The NICE concluded that the relatively small benefits they provide balanced against the overall cost of providing the treatments, including intensive monitoring for serious side effects, means that they cannot currently be considered good value for the taxpayer. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.</p><p>A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure that diagnostic and treatment capacity, and clinical pathway redesign and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.</p><p>The Government will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will also put Britain at the forefront of transforming treatment for dementia by backing more research into the disease. Part of this will be ensuring that we support manufacturers to develop products that are potentially cost effective to implement, and that new treatments assessed as clinically and cost effective are rolled out in a safe and timely way.</p><p>The Department funds dementia research via the National Institute for Health and Care Research (NIHR). Alongside Alzheimer’s Research UK, Alzheimer’s Society, and the People’s Postcode Lottery, the NIHR is funding the Blood Biomarker Challenge which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support diagnosis of dementia.</p> answering member printed Baroness Merron grouped question UIN HL2126 question first answered 08/11/2024 13:11:38 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1737286

registered interest
date	28/10/2024
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Forests: Commodities
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government when they plan to introduce forest risk due diligence regulations under Schedule 17 to the Environment Act 2021.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2077
answer	answer is ministerial correction date of answer 04/11/2024 answer text <p>We recognise the need to take action to ensure that UK consumption of forest risk commodities is not driving deforestation, and we will set out our approach to addressing this in due course.</p> answering member printed Baroness Hayman of Ullock question first answered 04/11/2024 17:25:00 answering member 4395 label Biography information for Baroness Hayman of Ullock
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1737287

registered interest
date	28/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the remarks by Baroness Merron on 9 October (HL Deb col 1995), whether the working group considering apheresis capacity intends to consult stakeholders, including (1) the Cell and Gene Therapy Catapult, and (2) the Advanced Therapy Treatment Centre network, prior to publishing its report.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2078
answer	answer is ministerial correction date of answer 04/11/2024 answer text <p>The apheresis working group was established to address issues around apheresis capacity and improve the resilience of stem cell supply for the United Kingdom. The working group is currently in the evidence gathering phase ahead of publishing its report in spring 2025.</p><p>The group is comprised of stakeholders from apheresis users, commissioning bodies, patient representatives, and subject matter experts. Each member has a responsibility for keeping wider stakeholders informed. The Cell and Gene Therapy Catapult is already represented within the working group. The catapult is responsible for coordination of the Advanced Therapy Treatment Centre network. Through submissions from, and engagement with, the Cell and Gene Therapy Catapult, a report is in preparation on apheresis capacity across users to be discussed at the next working group meeting.</p> answering member printed Baroness Merron question first answered 04/11/2024 16:50:29 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1736352

registered interest
date	22/10/2024
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Import Controls: Inflation
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to review the inflationary impact of the Border Target Operating Model.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1897
answer	answer is ministerial correction date of answer 04/11/2024 answer text <p>Defra continues to monitor and review the impacts of new controls introduced under the Border Target Operating Model (BTOM). We will work closely with industry, trade partners and enforcement agencies to minimise costs to trade and disruption, while continuing to protect our biosecurity.</p><p> </p><p>The Government’s modelling of the inflationary impact of the BTOM uses a peer-reviewed econometric model, including the impacts of non-tariff measures related to checks such as the cost of Export Health Certificates and port fees, and upstream impacts such as administrative processing time, training, certificates of origin and security deposits or guarantees when moving agricultural goods under licence.</p><p> </p><p>Analysis has indicated the BTOM policies would lead to an approximate increase in consumer food price inflation of less than 0.2 percentage points over a three-year period</p><p> </p><p>An outbreak of a major disease could have a much more significant impact. The 2001 outbreak of Foot and Mouth disease cost £12.8 billion in 2022 prices, £4.8 billion of which was cost to Government and £8 billion cost to the private sector.</p> answering member printed Baroness Hayman of Ullock question first answered 04/11/2024 15:37:05 answering member 4395 label Biography information for Baroness Hayman of Ullock
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1736353

registered interest
date	22/10/2024
answering body	Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	Treasury
hansard heading	Postal Services: Northern Ireland
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the UK's state of readiness for the implementation of new customs and parcel arrangements under the Windsor Framework from 31 March 2025.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1898
answer	answer is ministerial correction date of answer 05/11/2024 answer text <p>The Government is committed to implementing the new freight and parcel arrangements under the Windsor Framework in good faith and protecting the UK internal market. Businesses should be ready for the new arrangements by 31 March 2025.</p><p> </p><p>An intensive programme of engagement with operators and representatives from the freight and parcels sectors is underway. We will continue to engage with relevant stakeholders including businesses who send parcels to Northern Ireland, business representative organisations, and the wider customs and logistics sector, in order to ensure a smooth transition to the new arrangements. Most recently HMRC published additional guidance on 24 October, which can be found on gov.uk.</p> answering member printed Lord Livermore question first answered 05/11/2024 16:42:24 answering member 4559 label Biography information for Lord Livermore
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1736354

registered interest
date	22/10/2024
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Immigration Controls: EU Countries
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the adequacy of traffic management and driver welfare measures in the event of queues relating to the introduction of the European Union's Entry/Exit system.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1899
answer	answer is ministerial correction date of answer 05/11/2024 answer text <p>Government continues to work closely with the Kent and Medway Resilience Forum to ensure that well-rehearsed traffic management plans for freight and passenger traffic are in place ahead of the introduction of the European Union’s new Entry/Exit system (EES).</p><p>Driver welfare is an important factor during any disruption. KMRF has responsibility for providing welfare to freight and non-freight traffic during a period of significant congestion or gridlock on the road network in Kent. KMRF holds an established Driver Welfare Plan, this is currently being reviewed ahead of EES implementation.</p><p> </p> answering member printed Lord Hendy of Richmond Hill question first answered 05/11/2024 14:51:36 answering member 4972 label Biography information for Lord Hendy of Richmond Hill
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1736355

registered interest
date	22/10/2024
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Agricultural Products: UK Trade with EU
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what progress they have made on developing a sanitary and phytosanitary agreement with the European Union.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1900
answer	answer is ministerial correction date of answer 05/11/2024 answer text <p>Following their meeting in Brussels on 2 October, the President of the European Commission and the Prime Minister have agreed to strengthen the relationship between the EU and UK, putting it on a more solid, stable footing. We have already said we will seek to negotiate a UK-EU veterinary/SPS agreement to help boost trade and deliver benefits to businesses and consumers in the UK and the EU. The UK and EU are like-minded partners with similarly high standards. We recognise that delivering new agreements will take time, but we are ambitious, have clear priorities and want to move forward at pace.</p> answering member printed Baroness Hayman of Ullock question first answered 05/11/2024 15:54:21 answering member 4395 label Biography information for Baroness Hayman of Ullock
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick